GlassScriptPhysician profile
Niccole Blanchet
NPI 1174996839
$797.11
in general payments reported to CMS, 2019-2025
11 companies · $15.05 in 2025
The $15.05 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $394 · 2022: $173 · 2024: $215 · 2025: $15.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $252.13 | 2021-2022 | |
| Novo Nordisk INC | $124.99 | 2024 | |
| Boston Scientific Corporation | $89.92 | 2024 | |
| Lilly USA, LLC | $80.09 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.74 | 2022 | |
| Amarin Pharma, INC. | $40.62 | 2021 | |
| Eisai INC. | $37.42 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.21 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.15 | 2022 | |
| Glaxosmithkline, LLC. | $15.05 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niccole Blanchet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.